An Open-label, Single Administration Study to Characterize the Local Duration of Exposure of Triamcinolone Acetonide From FX006 in Patients With Osteoarthritis (OA) of the Knee

Trial Profile

An Open-label, Single Administration Study to Characterize the Local Duration of Exposure of Triamcinolone Acetonide From FX006 in Patients With Osteoarthritis (OA) of the Knee

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Mar 2015

At a glance

  • Drugs Triamcinolone (Primary)
  • Indications Osteoarthritis
  • Focus Pharmacokinetics
  • Sponsors Flexion Therapeutics
  • Most Recent Events

    • 25 Mar 2015 According to a Flexion Therapeutics media release, positive data was reported from in study in 2014.
    • 03 Nov 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 08 May 2014 Top-line data are expected during the second quarter of 2014, according to a Flexion Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top